Regen Biopharma Inc (RGBP) 0.2249 $RGBP
Regen BioPharma, Inc. Makes Three Presentations at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC
Marketwired - Tue May 05, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the Company has made presentations at 13th International Symposium on Myelodysplastic Syndromes held April 29 to May 2, 2015 in Washington, D.C.
Regen BioPharma Sees Opportunities Resulting from AACR Conference Attendance and Presentation
Marketwired - Mon Apr 27, 7:30AM CDT
Spokespersons for Regen BioPharma, Inc. (OTCBB: RGBP) (OTC PINK: RGBP) commented today regarding significant milestones presented by the Company at the 2015 American Association for Cancer Research Annual Meeting (AACR) as well as potential partnering opportunities that resulted from its presence at the event
Regen BioPharma, Inc. Engages Charles River Laboratories to Initiate FDA-Requested Study to Support Initiation of HemaXellerate Clinical Trial
Marketwired - Wed Apr 22, 7:31AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it has engaged Charles River Laboratories to initiate a Good Laboratory Practices (GLP) mouse toxicity study with regards to HemaXellerate. HemaXellerate, a therapy under development by Regen, is a cellular drug designed to heal damaged bone marrow.
Regen BioPharma Recruits Renowned Cancer Stem Cell Experts to Scientific Advisory Board
Marketwired - Thu Apr 16, 3:01PM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the recruitment of 3 internationally-renowned cancer stem cell experts to its scientific advisory board. The addition is a result of the company's increasing advances in the development of therapeutics targeting what is believed to be "the root of cancer" which is the cancer stem cell. The following is a description of the new members:
Regen BioPharma Narrows Selection of CRO Candidates for HemaXellerate GLP Safety Studies Requested by the FDA
Marketwired - Mon Apr 13, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP), (OTC PINK: RGBP) announced today that it has narrowed the Contract Research Organization (CRO) selection process to two candidates. The selected candidate will conduct the HemaXellerate Good Laboratory Practice (GLP) safety study requested by the US Food and Drug Administration ( FDA). This study will consist of an additional set of animal safety studies on HemaXellerate in preparation for submission to the FDA for permission to initiate "First in Human" use of HemaXellerate. HemaXellerate is a proposed therapeutic product for treating aplastic anemia.
Regen BioPharma Inc. Announces Small Molecule Drug Discovery Milestones at the American Association for Cancer Research's 2015 Annual Meeting
Marketwired - Thu Apr 09, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the acceptance of its abstract "Discovery of retinoic acids as low affinity inhibitors of the leukemia stem cell target NR2F6" at the American Association for Cancer Research Annual Meeting taking place April 18-22, 2015 in Philadelphia, Pennsylvania.
Regen BioPharma Inc. to Present Multiple Presentations at the 13th International Symposium on Myelodysplastic Syndromes
Marketwired - Tue Apr 07, 9:22AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the 13th International Symposium on Myelodysplastic Syndromes has accepted three presentations prepared by Regen BioPharma Inc. The accepted abstracts highlight the work being done in the Company's area of expertise in Aplastic Anemia and Myelodysplastic Syndrome. The link to the conference is http://mds.kenes.com
Regen BioPharma Expands Its Differentiation Therapy of Cancer Stem Cells Platform With Filing of Patent Applications on Silencing of NR2F2
Marketwired - Mon Apr 06, 11:00AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the expansion of its cancer stem cell intellectual property portfolio to include targeting of the gene NR2F2 (also known as COUP-TFII), a closely related family member to the cancer stem cell gene NR2F6, with the filing of two patent applications. Patent application #14588374 is for Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2 and patent application # 14588373 is for Methods and Compositions for treatment of cancer by inhibition of NR2F2.
Regen BioPharma CEO Discusses Recent Financings, New Laboratory Facilities and Preferred Stock Dividend
Marketwired - Wed Apr 01, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) Chairman & CEO David Koos provided the following update and clarification on recent financings done by the Company, along with new laboratory facilities and preferred stock dividend announcements:
Regen BioPharma Announces Presentation of DiffronC at Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics
Marketwired - Tue Mar 31, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that its abstract entitled "Development of DiffronC gene silencing technology for silencing of the novel leukemia stem cell target NR2F6" was accepted for presentation at the Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics, April 8 - 11, 2015.
Regen BioPharma, Inc. Expands Research Capacity With New Laboratory Facilities
Marketwired - Tue Mar 24, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the acquisition of new laboratory facilities in La Jolla area of San Diego, California. The laboratory space being leased by Regen is located within the Human BioMolecular Research Institute and provides the Company with access to molecular and cellular biology facilities critical to the Company's cancer stem cell research. Experimental studies in the new laboratory have commenced this week with an initial focus on performing pre-clinical experiments whose objective is the advancement of the Company's cancer stem cell and telomere therapeutic pipeline.
Regen Receives Green Light From FDA to Proceed With GLP Safety Study in Support of Its HemaXellerate Investigational New Drug Application
Marketwired - Tue Mar 17, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it has received final comments and authorization from the FDA to proceed with its GLP Safety Study in support of the company's HemaXellerate Investigational New Drug application (IND) which is on file with the FDA.
Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell
Marketwired - Tue Mar 10, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today successful closing of a transaction resulting in acquisition of issued US patent #8,263,571, and associated preclinical data package. The intellectual property covers specific therapeutic agents that gene silence CTCFL. CTCFL, otherwise known as Brother of the Regulator of Imprinted Sites (BORIS) is a gene that is critical for cancer stem cells to survive, in part by inducing expression of telomerase, a protein that creates cellular immortality(1).
Penny Stocks Report for Titan Pharmaceuticals, American Green, Banro, Globalstar, IFAN Financial, and Regen BioPharma
PR Newswire - Tue Mar 03, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Titan Pharmaceuticals (OTCBB:TTNP), American Green (OTCMKTS:ERBB), Banro (NYSEMKT:BAA), Globalstar (NYSEMKT:GSAT), IFAN Financial (OTCBB:IFAN), and Regen BioPharma (OTCBB:RGBP).
BAA: 0.31 (-0.03), GSAT: 2.56 (-0.03)
Regen BioPharma Inc. Files Patent Application for Treatment of Myelodysplastic Syndrome Utilizing Gene Silencing Therapy
Marketwired - Tue Mar 03, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the filing of patent application # 14,572/574 covering methods, compositions, and protocols for the treatment of myelodysplastic syndrome by gene silencing using Regen's proprietary siRNA therapeutic sequences platform.
Regen BioPharma, Inc. Expands Management Team With the Addition of New CFO Todd Caven
Marketwired - Tue Feb 17, 7:31AM CST
Regen BioPharma Inc. (OTC PINK: RGBP) announced that it has appointed Todd Caven to serve as the company's Chief Financial Officer. Mr. Caven is the cofounder of Saguaro Capital Partners, an Arizona based company that raises growth capital for medical device and technology companies throughout the United States., and Rock Ridge Enterprises LLC, a Minnesota-based Private Equity firm. Mr. Caven earned an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.
Regen BioPharma, Inc. Provides Update on Company's Progress and Areas of Specialization for 2015
Marketwired - Wed Jan 14, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) provided the following update on the Company's direction for 2015:
Regen BioPharma Inc. Identifies Second Generation Gene Silencing Candidates for Blocking Cancer Stem Cell Gene Target
Marketwired - Thu Jan 08, 7:31AM CST
Regen BioPharma Inc. (OTCBB: RGBP) announced today the discovery and demonstration of in vitro efficacy of a second generation of gene silencing drug candidates with specificity to the cancer stem cell gene NR2F6.
Regen BioPharma Presented Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at the American Society of Hematology Annual Meeting
Marketwired - Thu Dec 11, 7:57AM CST
Regen BioPharma Inc. (OTC PINK: RGBP) announced today it presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome at the American Society of Hematology Annual Meeting. This new drug target was identified by the Company's senior research consultant, Dr. Christine Ichim. A drug target is a gene involved in a disease which researchers aim to inhibit its function in order to treat the disease. Regen recently acquired intellectual property generated at the University of Toronto for inhibiting NR2F6.
Regen BioPharma, Inc. Makes Three Presentations at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC
Marketwired - Tue May 05, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the Company has made presentations at 13th International Symposium on Myelodysplastic Syndromes held April 29 to May 2, 2015 in Washington, D.C.
Regen BioPharma Sees Opportunities Resulting from AACR Conference Attendance and Presentation
Marketwired - Mon Apr 27, 7:30AM CDT
Spokespersons for Regen BioPharma, Inc. (OTCBB: RGBP) (OTC PINK: RGBP) commented today regarding significant milestones presented by the Company at the 2015 American Association for Cancer Research Annual Meeting (AACR) as well as potential partnering opportunities that resulted from its presence at the event
Regen BioPharma, Inc. Engages Charles River Laboratories to Initiate FDA-Requested Study to Support Initiation of HemaXellerate Clinical Trial
Marketwired - Wed Apr 22, 7:31AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it has engaged Charles River Laboratories to initiate a Good Laboratory Practices (GLP) mouse toxicity study with regards to HemaXellerate. HemaXellerate, a therapy under development by Regen, is a cellular drug designed to heal damaged bone marrow.
Regen BioPharma Recruits Renowned Cancer Stem Cell Experts to Scientific Advisory Board
Marketwired - Thu Apr 16, 3:01PM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the recruitment of 3 internationally-renowned cancer stem cell experts to its scientific advisory board. The addition is a result of the company's increasing advances in the development of therapeutics targeting what is believed to be "the root of cancer" which is the cancer stem cell. The following is a description of the new members:
Regen BioPharma Narrows Selection of CRO Candidates for HemaXellerate GLP Safety Studies Requested by the FDA
Marketwired - Mon Apr 13, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP), (OTC PINK: RGBP) announced today that it has narrowed the Contract Research Organization (CRO) selection process to two candidates. The selected candidate will conduct the HemaXellerate Good Laboratory Practice (GLP) safety study requested by the US Food and Drug Administration ( FDA). This study will consist of an additional set of animal safety studies on HemaXellerate in preparation for submission to the FDA for permission to initiate "First in Human" use of HemaXellerate. HemaXellerate is a proposed therapeutic product for treating aplastic anemia.
Regen BioPharma Inc. Announces Small Molecule Drug Discovery Milestones at the American Association for Cancer Research's 2015 Annual Meeting
Marketwired - Thu Apr 09, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the acceptance of its abstract "Discovery of retinoic acids as low affinity inhibitors of the leukemia stem cell target NR2F6" at the American Association for Cancer Research Annual Meeting taking place April 18-22, 2015 in Philadelphia, Pennsylvania.
Regen BioPharma Inc. to Present Multiple Presentations at the 13th International Symposium on Myelodysplastic Syndromes
Marketwired - Tue Apr 07, 9:22AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the 13th International Symposium on Myelodysplastic Syndromes has accepted three presentations prepared by Regen BioPharma Inc. The accepted abstracts highlight the work being done in the Company's area of expertise in Aplastic Anemia and Myelodysplastic Syndrome. The link to the conference is http://mds.kenes.com
Regen BioPharma Expands Its Differentiation Therapy of Cancer Stem Cells Platform With Filing of Patent Applications on Silencing of NR2F2
Marketwired - Mon Apr 06, 11:00AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the expansion of its cancer stem cell intellectual property portfolio to include targeting of the gene NR2F2 (also known as COUP-TFII), a closely related family member to the cancer stem cell gene NR2F6, with the filing of two patent applications. Patent application #14588374 is for Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2 and patent application # 14588373 is for Methods and Compositions for treatment of cancer by inhibition of NR2F2.
Regen BioPharma CEO Discusses Recent Financings, New Laboratory Facilities and Preferred Stock Dividend
Marketwired - Wed Apr 01, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) Chairman & CEO David Koos provided the following update and clarification on recent financings done by the Company, along with new laboratory facilities and preferred stock dividend announcements:
Regen BioPharma Announces Presentation of DiffronC at Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics
Marketwired - Tue Mar 31, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that its abstract entitled "Development of DiffronC gene silencing technology for silencing of the novel leukemia stem cell target NR2F6" was accepted for presentation at the Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics, April 8 - 11, 2015.
Regen BioPharma, Inc. Expands Research Capacity With New Laboratory Facilities
Marketwired - Tue Mar 24, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the acquisition of new laboratory facilities in La Jolla area of San Diego, California. The laboratory space being leased by Regen is located within the Human BioMolecular Research Institute and provides the Company with access to molecular and cellular biology facilities critical to the Company's cancer stem cell research. Experimental studies in the new laboratory have commenced this week with an initial focus on performing pre-clinical experiments whose objective is the advancement of the Company's cancer stem cell and telomere therapeutic pipeline.
Regen Receives Green Light From FDA to Proceed With GLP Safety Study in Support of Its HemaXellerate Investigational New Drug Application
Marketwired - Tue Mar 17, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it has received final comments and authorization from the FDA to proceed with its GLP Safety Study in support of the company's HemaXellerate Investigational New Drug application (IND) which is on file with the FDA.
Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell
Marketwired - Tue Mar 10, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today successful closing of a transaction resulting in acquisition of issued US patent #8,263,571, and associated preclinical data package. The intellectual property covers specific therapeutic agents that gene silence CTCFL. CTCFL, otherwise known as Brother of the Regulator of Imprinted Sites (BORIS) is a gene that is critical for cancer stem cells to survive, in part by inducing expression of telomerase, a protein that creates cellular immortality(1).
Penny Stocks Report for Titan Pharmaceuticals, American Green, Banro, Globalstar, IFAN Financial, and Regen BioPharma
PR Newswire - Tue Mar 03, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Titan Pharmaceuticals (OTCBB:TTNP), American Green (OTCMKTS:ERBB), Banro (NYSEMKT:BAA), Globalstar (NYSEMKT:GSAT), IFAN Financial (OTCBB:IFAN), and Regen BioPharma (OTCBB:RGBP).
BAA: 0.31 (-0.03), GSAT: 2.56 (-0.03)
Regen BioPharma Inc. Files Patent Application for Treatment of Myelodysplastic Syndrome Utilizing Gene Silencing Therapy
Marketwired - Tue Mar 03, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the filing of patent application # 14,572/574 covering methods, compositions, and protocols for the treatment of myelodysplastic syndrome by gene silencing using Regen's proprietary siRNA therapeutic sequences platform.
Regen BioPharma, Inc. Expands Management Team With the Addition of New CFO Todd Caven
Marketwired - Tue Feb 17, 7:31AM CST
Regen BioPharma Inc. (OTC PINK: RGBP) announced that it has appointed Todd Caven to serve as the company's Chief Financial Officer. Mr. Caven is the cofounder of Saguaro Capital Partners, an Arizona based company that raises growth capital for medical device and technology companies throughout the United States., and Rock Ridge Enterprises LLC, a Minnesota-based Private Equity firm. Mr. Caven earned an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.
Regen BioPharma, Inc. Provides Update on Company's Progress and Areas of Specialization for 2015
Marketwired - Wed Jan 14, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) provided the following update on the Company's direction for 2015:
Regen BioPharma Inc. Identifies Second Generation Gene Silencing Candidates for Blocking Cancer Stem Cell Gene Target
Marketwired - Thu Jan 08, 7:31AM CST
Regen BioPharma Inc. (OTCBB: RGBP) announced today the discovery and demonstration of in vitro efficacy of a second generation of gene silencing drug candidates with specificity to the cancer stem cell gene NR2F6.
Regen BioPharma Presented Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at the American Society of Hematology Annual Meeting
Marketwired - Thu Dec 11, 7:57AM CST
Regen BioPharma Inc. (OTC PINK: RGBP) announced today it presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome at the American Society of Hematology Annual Meeting. This new drug target was identified by the Company's senior research consultant, Dr. Christine Ichim. A drug target is a gene involved in a disease which researchers aim to inhibit its function in order to treat the disease. Regen recently acquired intellectual property generated at the University of Toronto for inhibiting NR2F6.
